TLC - Taiwan Liposome Company, Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.9100
-0.1000 (-2.00%)
As of 2:00PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close5.0100
Open4.9600
Bid4.8500 x 900
Ask4.9100 x 900
Day's Range4.9100 - 5.4500
52 Week Range2.4800 - 8.5400
Volume6,085
Avg. Volume3,248
Market Cap163.391M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-0.5060
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      TLC Highlights Findings in Abstract Accepted at Osteoarthritis Research Society International (OARSI) 2020 and Published in Osteoarthritis and Cartilage

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 18, 2020 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

    • GlobeNewswire

      TLC Reports First Quarter 2020 Financial Results and Provides Business Update

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 13, 2020 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

    • GlobeNewswire

      TLC Earns Highest Ranking in Corporate Governance Evaluation Six Years in a Row

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, May 04, 2020 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

    • Newsfile

      Encode Ideas, L.P. Announces the Initiation of Research Coverage on TLC

      Dover, Delaware--(Newsfile Corp. - April 27, 2020) - Encode Ideas, L.P. Initiates Research on TLC (NASDAQ: TLC) (TWO: 4152). The full research publication is available here and available on our website at www.encodelp.com. A summary follows:Encode Ideas, L.P., a healthcare focused research firm, announced today it is initiating coverage on TLC (NASDAQ: TLC) (TWO: 4152) as a high conviction idea. TLC is a leading drug delivery/reformulation company with two late-stage assets focused on pain, ...

    • GlobeNewswire

      TLC Announces Early Completion of Patient Enrollment in TLC590 Phase II Clinical Trial following Bunionectomy

      TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced the earlier-than-scheduled completion of patient enrollment in Part 2 of the TLC590 Phase II clinical trial, which is taking place across four sites in the United States. The randomized, double-blind, comparator- and placebo-controlled study will evaluate the analgesic efficacy and safety of TLC590 for postsurgical pain management in patients following bunionectomy.

    • GlobeNewswire

      TLC Reports Fiscal Year End 2019 Financial Results and Provides Business Update

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Feb. 11, 2020 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

    • GlobeNewswire

      TLC Announces Dosing of First Patients in Part 2 of TLC590 Phase II Trial for Postsurgical Pain following Bunionectomy

      TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced today that the first batch of patients has been dosed in Part 2 of the Phase II clinical trial for TLC590 in patients following bunionectomy surgery. TLC590 is a non-opioid, proprietary BioSeizer® sustained release formulation of ropivacaine intended to manage postsurgical pain for three days or more with a single dose, potentially reducing the need for opioids following surgery.

    • GlobeNewswire

      TLC to Present at 38th Annual JP Morgan Healthcare Conference

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 02, 2020 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

    • GlobeNewswire

      TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 27, 2019 (GLOBE NEWSWIRE) --  – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, announced today that the first patient has been enrolled in EXCELLENCE, the Phase III pivotal clinical trial for TLC599 in patients with osteoarthritis (OA) knee pain. TLC599 is a non-opioid, proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended to manage OA pain for up to six months.

    • Taiwan Liposome Sees Hammer Chart Pattern: Time to Buy?
      Zacks

      Taiwan Liposome Sees Hammer Chart Pattern: Time to Buy?

      Taiwan Liposome has been struggling lately, but the selling pressure may be coming to an end soon.

    • GlobeNewswire

      TLC Announces Completion of US$27 Million Financing

      TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, is pleased to announce that it has closed its 2019 cash capital offering of ordinary or common shares in Taiwan. The offering consisted of 10,200,000 new common shares issued at a price of NT$82 per common share for gross proceeds of NT$836,400,000 (~US$27.3 million).

    • GlobeNewswire

      TLC Reports Third Quarter 2019 Financial Results and Provides Business Update

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines.

    • GlobeNewswire

      TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine

      TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, recently presented data at the American Society of Anesthesiologists (ASA) ANESTHESIOLOGY® annual meeting from a Phase I/II clinical trial which showed TLC590 to yield more immediate and long-lasting pain reduction than ropivacaine. In addition, in vivo findings in which TLC590 showed no dose-related toxicity and other preclinical data were recently published in the International Journal of Nanomedicine.

    • GlobeNewswire

      TLC Appoints Vincent Chang, PhD, as Vice President of Manufacturing Development

      TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced the appointment of Vincent Chang, PhD, as TLC’s Vice President of Manufacturing Development. With over 35 years of experience attained at Abbott, Roche, GlaxoSmithKline and Bayer, Dr. Chang will serve as a member of the TLC Management Team and guide the company in affairs related to the chemistry, manufacturing and controls of its products.

    • GlobeNewswire

      TLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual Meeting

      TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, will be presenting magnetic resonance imaging (MRI) results of the potential protective effects of TLC599 on knee cartilage at the American College of Rheumatology 2019 ACR/ARP Annual Meeting in Atlanta, Georgia. TLC599 is a BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) which demonstrated durable pain relief and improved function over 24 weeks in patients with knee osteoarthritis pain in a Phase II clinical trial.

    • GlobeNewswire

      TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain

      TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced the initiation of a Phase III clinical trial (“EXCELLENCE”) to evaluate the efficacy and safety of single as well as repeated doses of TLC599 in patients with osteoarthritis (OA) of the knee. TLC599 is a BioSeizer® sustained release formulation of dexamethasone sodium phosphate (DSP) intended for the management of OA pain.

    • GlobeNewswire

      TLC to Present Preclinical Data on TLC178 at ESMO 2019

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development.

    • GlobeNewswire

      TLC to Present as Panelist among Key Opinion Leaders at the BTIG Pain Management Forum

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to.

    • GlobeNewswire

      TLC to Present at Upcoming Investor Conferences in September 2019

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Aug. 28, 2019 -- TLC (Nasdaq: TLC, TWO: 4152) today announced that the management team is scheduled to present at the two.

    • GlobeNewswire

      TLC Reports Second Quarter 2019 Financial Results and Provides Business Update

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, July 30, 2019 -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development.

    • GlobeNewswire

      TLC Announces Development and License Agreement with Birdie Biopharmaceuticals for NanoX™ Immunotherapy Product

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 25, 2019 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (“TLC”) (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced the signing of a development and license agreement with Birdie Biopharmaceuticals Inc. (“Birdie”), a wholly owned subsidiary of Seven and Eight Biopharmaceuticals Corp. Birdie and Seven and Eight Biopharmaceuticals are clinical stage biotech companies focused on the development of immunotherapy to treat cancer.

    • GlobeNewswire

      TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management following Bunionectomy

      TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced results from the pre-planned analysis of Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy. TLC590 is a proprietary BioSeizer® liposomal formulation of ropivacaine intended for the relief of postsurgical pain.

    • GlobeNewswire

      TLC Presents New Pharmacokinetic and Toxicokinetic Data on TLC599 Following Intra-articular Injection in Dogs at EULAR 2019

      SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, June 12, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines designed to target areas of unmet medical need in osteoarthritis, pain management, ophthalmology and oncology, today announced that new pharmacokinetic and toxicokinetic data are presented on TLC599 following intra-articular injections in dogs at the Annual European Congress of Rheumatology (EULAR 2019) on Thursday, June 13th in Madrid, Spain. Results from the study showed that TLC599, a proprietary BioSeizer® sustained release formulation of dexamethasone sodium phosphate, has the potential to be a long-lasting chronic treatment for osteoarthritis pain.